title: Novel agents for diffuse large B-cell lymphoma.
abstract: BACKGROUND
  Although diffuse large B-cell lymphoma (DLBCL) is commonly considered as a cancer with a high cure rate with conventional therapies recent studies demonstrate that different biological variants of DBLCL exist, and that patients with one DLBCL variant and DLBCL patients who relapse early following rituximab-based therapy have markedly poorer outcomes with conventional management strategies. Over the last decade, there has been an increasing exploration of novel therapies derived from improved understanding of DLBCL biology and tumor-host interactions.
  
  
  METHODS
  This review examines the biological basis for novel therapeutic approaches in DLBCL and the early clinical data on compounds derived from this research. A description of the expanding options of novel agents and combination therapies for patients with poor risk DLBCL is provided.
  
  
  CONCLUSIONS
  Several promising novel agents and novel therapeutic combinations are under development for patients with poor risk DLBCL. Carefully designed clinical trials that build on our improved understanding of DLBCL biology and utilize tissue samples to examine the activity of novel combination therapies should expand treatment options for DLBCL patients in the future.
authors: Emory University, Winship Cancer Institute, School of Medicine, Atlanta, GA 30322, USA.
authors: Rajni
authors: R
authors: Sinha
authors: Nutan
authors: N
authors: DeJoubner
authors: Christopher
authors: C
authors: Flowers
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*